Avalo Therapeutics (AVTX) Enterprise Value (2014 - 2026)
Avalo Therapeutics posted quarterly Enterprise Value of -$57.2 million for Q1 2026, up 54.3% year-on-year from -$37.0 million in Q1 2025, and up 30.74% on a QoQ basis from -$82.5 million in Q4 2025.
Avalo Therapeutics (AVTX) has 13 years of Enterprise Value data on file, last reported at -$57.2 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value rose 54.3% year-over-year to -$57.2 million; the trailing twelve-month figure through Mar 2026 stood at -$57.2 million (up 54.3% YoY), and the FY2025 full-year result was -$82.5 million, up 38.67% from the prior year.
- Enterprise Value for Q1 2026 stood at -$57.2 million, up from -$82.5 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$1000.0 in Q3 2023 and bottomed at -$134.5 million in Q4 2024.
- The 5-year median for Enterprise Value is -$57.2 million (2026), against an average of -$51.4 million.
- The widest annual swing landed in 2023, when Enterprise Value jumped 99.99%; it then plunged 13454500.0% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$15000.0 in 2022, then jumped by 93.33% to -$1000.0 in 2023, then slumped by 13454500.0% to -$134.5 million in 2024, then soared by 38.67% to -$82.5 million in 2025, then soared by 30.74% to -$57.2 million in 2026.
- The last three Enterprise Value figures came in at -$57.2 million (Q1 2026), -$82.5 million (Q4 2025), and -$84.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - | -57.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.15 Mn |
| Dec 31, 2025 | -82.52 Mn |
| Sep 30, 2025 | -84.74 Mn |
| Jun 30, 2025 | -70.99 Mn |
| Mar 31, 2025 | -125.05 Mn |
| Dec 31, 2024 | -134.55 Mn |
| Sep 30, 2024 | -81.86 Mn |
| Jun 30, 2024 | -93.43 Mn |
| Mar 31, 2024 | -110.18 Mn |
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -15,000.00 |
| Mar 31, 2023 | -16.69 Mn |
| Dec 31, 2022 | -15,000.00 |
| Sep 30, 2022 | -16.94 Mn |
| Jun 30, 2022 | -14,000.00 |
| Mar 31, 2022 | -100,000.00 |
| Dec 31, 2021 | -54.59 Mn |
| Sep 30, 2021 | -71.51 Mn |
| Jun 30, 2021 | -40.44 Mn |
| Mar 31, 2021 | -38.29 Mn |
| Dec 31, 2020 | -38,000.00 |
| Sep 30, 2020 | -132,000.00 |
| Jun 30, 2020 | -33,000.00 |
| Mar 31, 2020 | -14.77 Mn |
| Dec 31, 2019 | -7.65 Mn |
| Sep 30, 2019 | -102,214.00 |
| Jun 30, 2019 | -9.39 Mn |
| Mar 31, 2019 | -16.12 Mn |
| Dec 31, 2018 | -18,730.00 |
| Sep 30, 2018 | -37,027.00 |
| Jun 30, 2018 | -2.18 Mn |
| Mar 31, 2018 | -2.52 Mn |
| Dec 31, 2017 | -2.61 Mn |
| Sep 30, 2017 | -23.96 Mn |
| Jun 30, 2017 | -13,300.00 |
| Mar 31, 2017 | -3.00 Mn |
| Dec 31, 2016 | -5.20 Mn |
| Sep 30, 2016 | -8.82 Mn |
| Jun 30, 2016 | -11.88 Mn |
| Mar 31, 2016 | -16.60 Mn |
| Dec 31, 2015 | -21.16 Mn |
| Sep 30, 2015 | -3.31 Mn |
| Jun 30, 2015 | -6.14 Mn |
| Mar 31, 2015 | -8.66 Mn |
| Dec 31, 2014 | -11.74 Mn |
| Sep 30, 2014 | -15.73 Mn |